NRXP Insider Trading Activity and SEC Form 4 Filings
NRXP insider trading summary
No open-market insider purchases or sales of NRX Pharmaceuticals, Inc. (NRXP) have been reported on SEC Form 4 in the past 12 months.
Latest NRXP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 17, 2024 | Jonathan C Javitt | Chairman and Chief Scientist | Buy | $47K (40,000 @ $1.17) |
| Aug 30, 2023 | Aaron Gorovitz | Insider | Buy | $11K (35,000 @ $0.32) |
| Aug 30, 2023 | Chaim Hurvitz | Insider | Buy | $20K (70,000 @ $0.29) |
| Aug 23, 2023 | Jonathan C Javitt | Chief Scientist | Buy | $33K (100,000 @ $0.33) |
| Aug 22, 2023 | Jonathan C Javitt | Chief Scientist | Buy | $64K (200,000 @ $0.32) |
| Dec 16, 2022 | Voorhees Seth Van | Chief Financial Officer | Buy | $33K (30,000 @ $1.10) |
| Dec 16, 2022 | Stephen H Willard | Chief Executive Officer | Buy | $59K (50,000 @ $1.17) |
| Dec 7, 2022 | Jonathan C Javitt | Insider | Sell | $400K (400,000 @ $1.00) |
| Nov 30, 2022 | Daniel C. Javitt | 10% Owner | Sell | $13K (8,441 @ $1.50) |
| Nov 29, 2022 | Daniel C. Javitt | 10% Owner | Sell | $21K (13,730 @ $1.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.